In fiscal year 2014, this Core continues to microinject constructs for the Mouse Cancer Genetics Program and their collaborators;both linear derived fragments of genomic DNA and BAC clones have been microinjected into the pronucleus of inbred and F2 hybrid mouse strains, depending on the goal of the experiment. In Fall of 2013 we started working with the CRISPR/Cas9 technology, the new evolution of creating targeted mutations in mice. With the CRISPR/Cas9 technology mutations can be introduced into multiple genes at the same time by injecting multiple gRNAs into the cytoplasm or injecting a plasmid using the CRISPR/Cas9 technology into the pronucleus of fertilized eggs. In 2014, and in the years to come, we hope to save the MCGP both time and money with this new technology, when it comes to creating targeted mutation mice. We continue to perform in vitro fertilization (IVF), which we started in fiscal year 2010. IVF of MCGP mouse lines is a way to accelerate colony expansion for experimental research. IVF is a way to rapidly expand a mouse colony to generate large numbers of age, sex &genotypically matched cohorts for experimental use without vastly expanding the number of breeding cages on the shelf. With IVF we can save on cage space, time, and costs as well as accelerate the time it takes to initiate experiments, IVF is basically a more efficient means to expand a mouse colony in a short amount of time. Another way we are trying to save money is to maintain colonies of mice that we use in great quantity or mice that are extremely expensive to buy;those lines include Athymic nudes, Jax B6.CB17-Scid, C57BL/6J, FVB/NJ and B6D2F1/J. In August of 2012 our Core started maintaining 4 Cre and reporter lines used most often by MCGP Labs. With the TFC maintaining these lines there is 1 colony of each line being maintained instead of each lab having their own individual colony and the TCF acts as a central distribution center, (an average cost on many of these Cre or Flpe lines coming from Jax is $232/mouse, just the cost of 4 of these mice would cover the cost of keeping six cages of mice on the shelf for a year). We also provide mice to other investigators in CCR &CAPR as requests come in, always making sure MTA's are filled out if needed. We continued performing injections/bleeds for two labs, Brad St. Croix &Terry Van Dyke. Also for Terry Van Dyke's Lab we continued performing castrations for prostate cancer studies. We continue to train Post-docs and technicians on various procedures involving the mice and mouse work, as we receive requests. For our microinjection Core, we continue to set up an average of 150 - 200 timed pregnancies per week/40 weeks/year, vasectomize 400 mice per year, send out animal shipments as well as interbuilding transfers, for which we initiated all Material Transfer Agreements for the investigators, as needed. A full list of services we provide investigators include microinjection, IVF, surgeries (which include embryo transfers, vasectomies, castrations, ovary transfers, ovariectomies, splenectomies mammary biopsies, mammary fat pad injections and intraductal mammary gland injections), breeding, weaning, tail biopsies, timed pregnancies, necropsies, palpation &measurement of tumors, injections, blood collection, rederivation, photography, monitoring aging studies, sending animals to histopathology, train technicians, post-docs and investigators how to perform different procedures, initiate material transfer agreements, arrange animal shipments, data entry and database management. The Transgenic Core Facility makes its own media and anesthetics used within the facility. We acid wash all of our own glassware, make all our own injection needles, holding pipettes and transfer pipettes. The Transgenic Core Facility also makes all our own microinjection dishes, which allows the injector to work with 150-200 embryos at a time instead of the standard 50 that depression slides hold. The Transgenic Core Facility is truly a multifaceted operation in that we can take care of just one aspect of a researchers mouse colony needs or we can manage the entire colony from the creation of the transgenic mice lines to the lines final disposition and run all their experiments. In 2014 we performed work for 11 different labs, maintaining experimental mouse lines for five of the 11 labs. The labs we are either managing the mouse colonies, training personnel, running mouse experiments and/or labs we have performed microinjection, in vitro fertilization and/or surgeries for in 2014 are all listed below. Neural Development Section - Lino Tessarollo, Tumor Angiogenesis Section - Brad St. Croix, Genetics of Cancer Susceptibility Section - Shyam Sharan, Vascular Biology Section - P. Charles Lin, Epigenetics Section - Kathrin Muegge, Cancer Pathways and Mechanisms - Terry Van Dyke, Genetic Modifiers of Tumorigenesis Section - Karlyne Reilly, Genetics of Vertebrate Development Section - Mark Lewandoski, Stem Cell Regulation and Animal Aging Section - Steven Hou, Principal Scientist and Program Manager, CAPR - Serguei Koslov, Gene Regulation and Chromosome Biology Laboratory - Jeffery Strathern,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC010903-07
Application #
8938434
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A 115:1635-1640
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2017) Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and ?-Synuclein Pathology. eNeuro 4:
Jiang, Jie; Zhu, Qiang; Gendron, Tania F et al. (2016) Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron 90:535-50
Basheer, Wassim A; Harris, Brett S; Mentrup, Heather L et al. (2015) Cardiomyocyte-specific overexpression of the ubiquitin ligase Wwp1 contributes to reduction in Connexin 43 and arrhythmogenesis. J Mol Cell Cardiol 88:1-13
Lee, Yunjong; Karuppagounder, Senthilkumar S; Shin, Joo-Ho et al. (2015) Corrigendum: Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 18:1861
Herriges, John C; Verheyden, Jamie M; Zhang, Zhen et al. (2015) FGF-Regulated ETV Transcription Factors Control FGF-SHH Feedback Loop in Lung Branching. Dev Cell 35:322-32
Vitre, Benjamin; Holland, Andrew J; Kulukian, Anita et al. (2015) Chronic centrosome amplification without tumorigenesis. Proc Natl Acad Sci U S A 112:E6321-30
Posokhova, Ekaterina; Shukla, Animesh; Seaman, Steven et al. (2015) GPR124 functions as a WNT7-specific coactivator of canonical ?-catenin signaling. Cell Rep 10:123-30
Tebbenkamp, Andrew T N; Xu, Guilian; Siemienski, Zoe B et al. (2014) Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models. J Huntingtons Dis 3:73-86
Xu, Lihong; Stevens, Janine; Hilton, Mary Beth et al. (2014) COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med 6:242ra84

Showing the most recent 10 out of 23 publications